US FDA Commissioner Scott Gottlieb is defending the accelerated approval pathway in response to payors who have balked at covering high-priced products cleared under what they perceive to be a lower regulatory standard than the traditional approval process.
Speaking during the National Organization for Rare Disorders’ “Rare Summit” on Oct. 17, Gottlieb acknowledged “some instances” in which payors...







